LIXT Stock Price, Lixte Biotechnology Holdings, . Quote, Chart

Market Summary

USD3.11-0.15

Market Closed

-4.60%

LIXT Stock Price

View Fullscreen

LIXT RSI Chart

LIXT Valuation

Market Cap

7.3M

Price/Earnings (Trailing)

-1.44

Price/Sales (Trailing)

419.35

Price/Free Cashflow

-1.71

LIXT Price/Sales (Trailing)

LIXT Profitability

Return on Equity

-127.34%

Return on Assets

-118.07%

Free Cashflow Yield

-58.55%

LIXT Fundamentals

LIXT Revenue

Revenue (TTM)

17.5K

LIXT Earnings

Earnings (TTM)

-5.1M

Earnings Growth (Yr)

36.72%

Earnings Growth (Qtr)

-1.32%

Breaking Down LIXT Revenue

52 Week Range

0.479.50

(Low)(High)

Last 7 days

-6.0%

Last 30 days

-7.4%

Last 90 days

63.8%

Trailing 12 Months

492.7%

How does LIXT drawdown profile look like?

LIXT Financial Health

Current Ratio

13.73

LIXT Investor Care

Shares Dilution (1Y)

35.02%

Diluted EPS (TTM)

-2.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	12.8K	14.3K	15.9K	17.5K
2022	0	0	0	11.2K
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	200.0K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lixte Biotechnology Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 03, 2023	bernards rene	bought	13,872	2.51	5,527	-
Oct 03, 2023	van der baan bastiaan jeroen	bought	28,000	2.8	10,000	president and ceo
Oct 02, 2023	bernards rene	bought	10,243	2.29	4,473	-
Dec 30, 2022	van der baan bastiaan jeroen	bought	4,900	0.49	10,000	-
Dec 30, 2022	van der baan bastiaan jeroen	bought	49,000	4.9	10,000	-
Dec 15, 2022	bernards rene	bought	7,650	0.51	15,000	-
Dec 12, 2022	bernards rene	bought	6,100	0.61	10,000	-
Dec 09, 2022	forman eric	bought	9,836	0.61048	16,112	vice president and coo

Which funds bought or sold LIXT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Feb 14, 2024	CLEAR STREET LLC	unchanged	-	-1,000	1,000	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	111	2,667	5,262	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-711	16,699	-%
Feb 12, 2024	JPMORGAN CHASE & CO	sold off	-100	-2.00	-	-%
Feb 12, 2024	HighTower Advisors, LLC	new	-	234,000	234,000	-%
Feb 09, 2024	UBS Group AG	new	-	8.00	8.00	-%
Feb 09, 2024	UBS Group AG	new	-	7.00	7.00	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	unchanged	-	-1.00	21.00	-%
Feb 07, 2024	Warberg Asset Management LLC	unchanged	-	-1,042	1,533	-%
Feb 07, 2024	Ethos Financial Group, LLC	sold off	-100	-60,780	-	-%

Are Funds Buying or Selling LIXT?

Are funds buying LIXT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIXT

No. of Funds

Unveiling Lixte Biotechnology Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 07, 2022	forman eric	075%	1,104,431	SC 13G/A
Apr 07, 2022	krinsky glenn	10.73%	1,474,998	SC 13G
Jan 04, 2022	sabby management, llc	12.%	0	SC 13G/A
Mar 03, 2021	sabby management, llc	7.99%	1,081,081	SC 13G
Dec 17, 2020	greenberg robert	11.15%	1,380,264	SC 13G/A
Dec 17, 2020	forman eric	11.38%	1,417	SC 13G/A
Dec 17, 2020	schwartzberg gil	16.2%	2,144,985	SC 13G/A
Dec 17, 2020	ho hung tak	8.73%	1,084,210	SC 13G/A
Dec 17, 2020	kovach john s	12.6%	1,561,283	SC 13D/A

Recent SEC filings of Lixte Biotechnology Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	S-3	S-3
Mar 28, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 19, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 26, 2024	8-K	Current Report
Jan 30, 2024	8-K	Current Report

Peers (Alternatives to Lixte Biotechnology Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.2	12.55	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.93	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Lixte Biotechnology Holdings, Inc. News

Latest updates

Lixte Biotechnology Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Operating Expenses	0.2%	1,026	1,024	1,670	1,370	1,633	1,479	1,546	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-10.1%	320	356	523	519	584	644	754	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	12.5%	149	132	427	189	454	272	165	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	3536.2%	10.00	279*	2.00	4.00	4.00	2.00	627*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-1.3%	-1,032	-1,018	-1,668	-1,367	-1,631	-1,478	-1,546	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income Margin	-Infinity%	-290.92*	-	-	-4.60*	-4.82*	-5.13*	-5.51*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	4.5%	-902	-944	-1,175	-1,271	-1,208	-1,173	-1,194	-1,146	-	-	-	-739	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.7%	4,309	5,235	3,095	4,331	5,561	6,819	8,024	4,118	5,093	6,334	7,243	7,890	5,228	1,362	1,892	2,276	2,672	3,066	3,619	3,955	4,337
Current Assets	-17.7%	4,309	5,235	3,095	4,331	5,561	6,819	8,024	4,107	5,093	6,307	7,243	7,890	5,228	1,188	1,805	2,276	2,672	3,066	3,619	3,955	4,334
Cash Equivalents	-17.7%	4,203	5,106	2,913	4,088	5,353	6,562	7,736	3,778	4,824	5,961	6,798	7,739	5,069	1,076	1,774	2,185	2,599	2,976	3,564	3,894	4,273
Current Liabilities	0.7%	314	312	403	250	396	408	532	645	303	259	376	242	217	221	214	225	238	309	223	245	211
Shareholder's Equity	-18.9%	3,995	4,923	2,693	4,081	5,165	6,411	7,492	3,473	4,790	6,075	6,866	7,648	5,012	1,141	1,678	2,051	2,434	2,756	3,396	3,710	4,126
Retained Earnings	-2.2%	-48,481	-47,449	-46,430	-44,762	-43,394	-41,763	-40,285	-38,739	-37,082	-35,052	-33,814	-32,080	-30,353	-29,446	-27,845	-27,472	-27,088	-26,766	-25,687	-25,077	-24,648
Additional Paid-In Capital	0.2%	48,976	48,872	45,623	45,342	45,060	44,673	44,276	38,711	38,371	37,626	37,179	36,227	31,864	27,081	26,016	26,016	26,022	26,016	25,577	25,281	25,268
Shares Outstanding	0%	2,249	2,249	1,666	1,666	1,665	1,665	1,620	1,375	1,375	1,338	1,363	1,277	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,125	-	-	-	2,400	-	-	-	30,550	-	-	-	13,193	-	-	-	14,659	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	4.5%	-902	-944	-1,175	-1,271	-1,208	-1,173	-1,194	-1,035	-1,146	-927	-1,041	-1,026	-739	-623	-354	-414	2,971	-587	-329	-379	-576
Share Based Compensation	-7.2%	104	112	280	277	385	397	424	340	347	347	-	656	-37.85	464	-	-	-33.00	32.00	-	-	-
Cashflow From Financing	-100.0%	-	3,137	-	6.00	-	-	5,152	-10.91	10.00	90.00	101	3,696	4,732	-74.39	-	-	-	-	-	-	4,475

LIXT Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenues
General and administrative costs:
Compensation to related parties, including stock-based compensation of $773,203 and $1,502,776 for the years ended December 31, 2023 and 2022, respectively	1,718,180	2,547,615
Patent and licensing legal and filing fees and costs	978,244	1,268,308
Other costs and expenses	1,495,712	1,146,289
Research and development costs, including $0 and $43,264 of stock-based compensation costs to a consultant for the years ended December 31, 2023 and 2022, respectively	898,100	1,349,269
Total costs and expenses	5,090,236	6,311,481
Loss from operations	(5,090,236)	(6,311,481)
Interest income	17,486	11,195
Interest expense	(16,233)	(8,875)
Foreign currency gain (loss)	1,954	(3,374)
Net loss	$ (5,087,029)	$ (6,312,535)
Net loss per common share basic	$ (2.66)	$ (3.99)
Net loss per common share diluted	$ (2.66)	$ (3.99)
Weighted average common shares outstanding basic	1,915,838	1,582,029
Weighted average common shares outstanding diluted	1,915,838	1,582,029

LIXT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 4,203,488	$ 5,353,392
Advances on research and development contract services	78,016	147,017
Prepaid insurance	17,116	49,224
Other prepaid expenses	10,000	11,350
Total current assets	4,308,620	5,560,983
Total assets	4,308,620	5,560,983
Current liabilities:
Accounts payable and accrued expenses, including $36,250 and $46,982 to related parties at December 31, 2023 and 2022, respectively	156,758	230,734
Research and development contract liabilities	157,100	165,022
Total current liabilities	313,858	395,756
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference based on assumed conversion into common shares – 72,917 shares	3,500,000	3,500,000
Common stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290 shares and 1,664,706 shares at December 31, 2023 and 2022, respectively	225	166
Additional paid-in capital	48,976,265	45,059,760
Accumulated deficit	(48,481,728)	(43,394,699)
Total stockholders’ equity	3,994,762	5,165,227
Total liabilities and stockholders’ equity	$ 4,308,620	$ 5,560,983

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

CEO	Dr. John S. Kovach M.D.
WEBSITE	https://lixte.com
INDUSTRY	Biotechnology
EMPLOYEES	3

Lixte Biotechnology Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Lixte Biotechnology Holdings, Inc.? What does LIXT stand for in stocks?

LIXT is the stock ticker symbol of Lixte Biotechnology Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lixte Biotechnology Holdings, Inc. (LIXT)?

As of Fri Apr 26 2024, market cap of Lixte Biotechnology Holdings, Inc. is 7.33 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIXT stock?

You can check LIXT's fair value in chart for subscribers.

What is the fair value of LIXT stock?

You can check LIXT's fair value in chart for subscribers. The fair value of Lixte Biotechnology Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lixte Biotechnology Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIXT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lixte Biotechnology Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether LIXT is over valued or under valued. Whether Lixte Biotechnology Holdings, Inc. is cheap or expensive depends on the assumptions which impact Lixte Biotechnology Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIXT.

What is Lixte Biotechnology Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, LIXT's PE ratio (Price to Earnings) is -1.44 and Price to Sales (PS) ratio is 419.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIXT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lixte Biotechnology Holdings, Inc.'s stock?

In the past 10 years, Lixte Biotechnology Holdings, Inc. has provided 0.33 (multiply by 100 for percentage) rate of return.